Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject must voluntarily sign and understand written informed consent.~* Histologically confirmed Durie-Salomon stage II or III MM (see Appendix II). Stage I MM patients will be eligible if they display poor prognostic factors (ß2M \> or = 5.5 mg/L, plasma cell proliferation index \> or = 5%, albumin of less then 3.0, and unfavorable cytogenetics).~* Measurable disease as defined by \> 1.0 g/dL serum monoclonal protein, \>0.1 g/dL serum free light chains, \> 0.2 g/24 hrs urinary M-protein excretion, and/or measurable plasmacytoma(s).~* Age \> or = 18 years at the time of signing the informed consent form.~* Karnofsky performance status \> or = 70% (\>60% if due to bony involvement of myeloma (see Appendix V).~* No prior treatment or less than one full course of first-line therapy. Patients may be receiving adjuvant antiresorptive therapy (i.e., pamidronate or zoledronic acid) as routine care.~* If the patient is a woman of childbearing age, she must have a negative serum or urine pregnancy test within 7 days of starting study.~* Due to the unknown risk of teratogenic side effects, subjects (women and men) must agree to use effective contraception throughout the duration of the study and for at least 1 month after discontinuation of study drugs.~* Life expectancy \> 3 months~* Absolute neutrophil count (ANC)\> or = 1000 cells/mm3 (1.0 x 109/L)~* Platelets count \> or = 75,000/mm3 (75 x 109/L)~* Serum SGOT/AST \< 3.0 x upper limits of normal (ULN)~* Serum SGPT/ALT \< 3.0 x upper limits of normal (ULN)~* Serum creatinine \< 2.5 mg/dL (221 µmol/L)~* Serum total bilirubin \< 2.0 mg/dL (34 µmol/L)~Exclusion Criteria:~* Patients with non-secretory MM (no measurable monoclonal protein, free light chains, and/or M-spike in blood or urine).~* Prior history of other malignancies (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless disease free for ³ 5 years.~* NYHA Class III or IV heart disease. History of active angina, congestive heart disease, or myocardial infarction within 6 months.~* Pregnant or lactating women are ineligible.~* Known HIV positivity~* Active viral or bacterial infections or any coexisting medical problem that would significantly increase the risks of this treatment program.~* Known hypersensitivity to dexamethasone, clarithromycin, lenalidomide, or thalidomide.~* Prior therapy for the treatment of MM~* History of thromboembolic event or other condition currently requiring anticoagulation with warfarin (Coumadin). Patients whose therapy is changed to heparin are eligible.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).